Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
5 hedge funds and large institutions have $192K invested in Reviva Pharmaceuticals Warrants in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.
9.17% less ownership
Funds ownership: 10.12% → 0.95% (-9.2%)
17% less funds holding
Funds holding: 6 → 5 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
34% less capital invested
Capital invested by funds: $292K → $192K (-$100K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$11.2K |
| 2 |
NC
NewSquare Capital
Newtown Square,
Pennsylvania
|
+$427 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$239K |
| 2 |
Walleye Capital
New York
|
-$30.1K |
| 3 |
Walleye Trading
New York
|
-$21.2K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
Arena Investors
Purchase,
New York
| $84.2K | – | – | – |
|
|
2
Walleye Capital
New York
| $53.8K | -$30.1K | -35,307 | -39% |
|
|
3
Walleye Trading
New York
| $40.5K | -$21.2K | -24,793 | -38% |
|
|
VF
4
Virtu Financial
New York
| $13K | +$11.2K | +13,091 | New |
|
|
NC
5
NewSquare Capital
Newtown Square,
Pennsylvania
| $495 | +$427 | +500 | New |
|
|
BCM
6
BlueCrest Capital Management
St Helier,
Jersey
| – | -$239K | -1,251,250 | Closed |
|
|
AA
7
AQR Arbitrage
Greenwich,
Connecticut
| – | -$6K | -32,704 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$1K | -6,901 | Closed |
|
RVPHW Hedge Fund Activity: Q4 2022 in Review
5 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q4 2022, worth a combined $192K — down 34% from $292K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of RVPHW and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $11.2K. The largest seller was BlueCrest Capital Management, exiting entirely with an estimated $239K sold.
- 5 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q4 2022, down from 6 in Q3 2022.
- Funds reported $192K of Reviva Pharmaceuticals Warrants stock for Q4 2022, down 34% quarter-over-quarter.
- 2 funds opened new Reviva Pharmaceuticals Warrants positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest Reviva Pharmaceuticals Warrants buyer in Q4 2022 was Virtu Financial, an estimated $11.2K added.
- The largest Reviva Pharmaceuticals Warrants seller in Q4 2022 was BlueCrest Capital Management, an estimated $239K sold.
Based on aggregated 13F filings for Q4 2022.